| Title: | Amgen at Lehman Brothers Healthcare Conference Transcript |
| Price: | $54.00 |
| Publication Date: | Mar 19, 2008 |
| Source: | Thomson StreetEvents |
| Report Type: | Transcript |
| Abstract: | Final Transcript of AMGN presentation, 19-Mar-08 8:00am ET |
| Brief Excerpt: | ... - Lehman Brothers - AnalystOkay, I think we're going to get started with our first session of the morning. I'm Jim Birchenough, Senior Analyst at Lehman. It's my pleasure to introduce our next speaker, Dr. Roger Perlmutter, who is Head of R&D at Amgen, and Executive Vice President. It goes without saying that Amgen has faced a number of challenges over the last ## months from both CMS and FDA, and even the District Court of Massachusetts recently. But I remind everyone that Amgen does have another large portfolio of products with Enbrel and Neulasta, and a very exciting pipeline opportunity coming up with Denosumab, so we're really happy to have Roger here to put all that in perspective for us. ... |
| Word Count: | 4937 |
| Length: | 8 Pages |
| Ticker: | AMGN |
| Time: | 8:00am ET |
| Related Report(s): | |
| Format: | 
Adobe Acrobat
|
| Free Sample: |
Click
Here
to Download
|
Looking For Something Else?
